Eli Lilly's new Alzheimer's drug, donanemab, received approval from an advisory panel for the FDA. The full agency is expected to approve the drug by spring.
gained the support of a federal advisory panel Monday, paving the way for it to become the second drug of its kind authorized in the United States.voted unanimously Monday afternoon that the drug’s ability to slow disease progression outweighs the drug’s potentially severe side effects, including brain swelling and bleeding.
The clinical trials for donanemab conducted by Eli Lilly grouped patients based on their levels of tau, a brain protein whose presence predicts the severity of cognitive problems and decline. Critics of donanemab are concerned about the severity of side effects that may appear, on the surface, to be stroke-like symptoms. The group concluded that it may become part of FDA recommendation guidelines that patients taking donanemab be advised to carry a card indicating that it is on their prescription list to inform physicians in the event of an emergency.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA advisors recommend Eli Lilly's Alzheimer's drug donanemab, paving way for approvalIf approved, Eli Lilly’s donanemab would become the second Alzheimer’s drug of its kind to enter the market after Leqembi from Biogen and Eisai.
Read more »
FDA advisors recommend Eli Lilly's Alzheimer's drug donanemab, paving way for approvalIf approved, Eli Lilly's donanemab would become the second Alzheimer's drug of its kind to enter the market after Leqembi from Biogen and Eisai.
Read more »
FDA analysis raises no major concerns about Eli Lilly Alzheimer's drugAn FDA analysis of trial data for Eli Lilly's experimental Alzheimer's drug donanemab released on Thursday revealed no red flags, but raised questions about safety of the treatment for patients with early-stage disease.
Read more »
Alphabet names Eli Lilly veteran Ashkenazi as CFOAlphabet names Eli Lilly veteran Ashkenazi as CFO
Read more »
Alphabet taps Eli Lilly's Anat Ashkenazi as new CFOThe new Google executive will replace Ruth Porat, who will become president and chief investment officer of the company after nearly a decade as CFO.
Read more »
Eli Lilly's diabetes drug tirzepatide gets approval in ChinaEli Lilly's diabetes drug tirzepatide gets approval in China
Read more »